Zilovertamab vedotin Market Summary

Key Factors Driving Zilovertamab vedotin Growth

1. Promising activity in B-cell malignancies, particularly DLBCL and mantle cell lymphoma (MCL):

Zilovertamab vedotin targets ROR1, an oncofetal receptor expressed on several hematologic malignancies, and delivers the microtubule inhibitor MMAE directly to ROR1-positive cells. In the first-in-human Phase I study, 7/15 patients with MCL (47%) and 3/5 patients with DLBCL (60%) achieved objective responses despite a median of four prior therapies. These findings provided clinical proof-of-concept for ROR1-directed therapy and established the rationale for subsequent development.

2. Very strong early results in previously untreated DLBCL could support a major first-line opportunity:

The Phase II waveLINE-007 study is evaluating zilovertamab vedotin + R-CHP in previously untreated DLBCL. At the recommended 1.75 mg/kg dose, all 15 evaluable patients achieved a complete response (100%), while the overall CR rate across all dose groups was 97.2%. The 12-month duration-of-response rate was 93.5%, with median DOR not reached at a median follow-up of 17.6 months. These results led Merck to select 1.75 mg/kg as the recommended dose for Phase III development.

3. Large addressable DLBCL population provides substantial commercial potential:

DLBCL is the most common form of non-Hodgkin lymphoma and accounts for approximately 25–30% of NHL cases worldwide. Merck estimates approximately 25,000 patients are diagnosed with DLBCL annually in the U.S. Although frontline treatment with R-CHOP or related regimens produces durable responses for many patients, a substantial proportion eventually relapse or become refractory. Merck has cited an unmet need for additional first-line options because approximately 40% of patients experience relapsed/refractory disease after initial treatment. Successful Phase III development could therefore place zilovertamab vedotin in a large treatment population.

4. Multiple Phase III hematology programs diversify the potential revenue opportunity:

Merck's current pipeline lists zilovertamab vedotin in Phase III hematologic-malignancy development, with programs including waveLINE-003, waveLINE-004, waveLINE-006 and waveLINE-007, alongside additional development through waveLINE-010. This suggests that Merck is pursuing the molecule across multiple lymphoma settings rather than relying on a single indication. Successful results in more than one setting could substantially increase its eventual addressable population.

5. ROR1 represents a differentiated target for ADC development:

Zilovertamab vedotin uses an antibody against the extracellular domain of ROR1, linked through a cleavable linker to MMAE. ROR1 is expressed in several malignant B-cell populations while having limited expression in most normal adult tissues, providing a biological rationale for selective tumor targeting. The Phase I study demonstrated exposure-dependent targeting of ROR1 on circulating tumor cells and did not identify unexpected ROR1-mediated toxicity, supporting continued investigation of this mechanism.

Zilovertamab vedotin Recent Developments

In February 2025, Merck, known as MSD outside of the United States and Canada, today announced the initiation of waveLINE-010, a pivotal Phase III clinical trial evaluating zilovertamab vedotin in combination with rituximab plus cyclophosphamide, doxorubicin and prednisone (R-CHP) compared to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) alone, for the treatment of patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Zilovertamab vedotin is Merck’s investigational antibody-drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1). Global recruitment of the waveLINE-010 trial has begun, with patients now enrolling.

“Zilovertamab vedotin Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Zilovertamab vedotin for potential indication like Diffuse large B cell lymphoma, Bladder cancer, Breast cancer, Chronic lymphocytic leukaemia, Follicular lymphoma, Gastric cancer, Haematological malignancies, Mantle-cell lymphoma, Non-small cell lung cancer, Ovarian cancer, and Pancreatic cancer in the 7MM. A detailed picture of Zilovertamab vedotin’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Zilovertamab vedotin for potential indications. The Zilovertamab vedotin market report provides insights about Zilovertamab vedotin’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Zilovertamab vedotin performance, future market assessments inclusive of the Zilovertamab vedotin market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Zilovertamab vedotin sales forecasts, along with factors driving its market.

Zilovertamab vedotin Drug Summary

Zilovertamab vedotin is an investigational antibody–drug conjugate (ADC) developed by Merck (MSD) for the treatment of certain B-cell malignancies. The drug is designed to target ROR1 (receptor tyrosine kinase-like orphan receptor 1), a cell-surface protein expressed on various hematologic cancers and several solid tumors but generally absent or expressed at low levels in most normal adult tissues. Zilovertamab vedotin consists of a monoclonal antibody directed against ROR1 linked to the cytotoxic payload monomethyl auristatin E (MMAE) through a protease-cleavable linker. Following intravenous administration, the antibody component binds to ROR1-expressing tumor cells and facilitates internalization of the ADC; intracellular cleavage releases MMAE, which disrupts microtubule function, causes cell-cycle arrest, and ultimately induces tumor-cell death. The drug has been investigated in clinical studies involving patients with mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, and other ROR1-expressing malignancies, including studies evaluating its use alone and in combination with established therapies. Zilovertamab vedotin remains an investigational therapy, with its clinical development focused on determining its safety, antitumor activity, and potential role in treating ROR1-positive cancers. The report provides Zilovertamab vedotin’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Zilovertamab vedotin Market Report

The report provides insights into:

• A comprehensive product overview including the Zilovertamab vedotin MoA, description, dosage and administration, research and development activities in potential indication like Diffuse large B cell lymphoma, Bladder cancer, Breast cancer, Chronic lymphocytic leukaemia, Follicular lymphoma, Gastric cancer, Haematological malignancies, Mantle-cell lymphoma, Non-small cell lung cancer, Ovarian cancer, and Pancreatic cancer.
• Elaborated details on Zilovertamab vedotin regulatory milestones and other development activities have been provided in Zilovertamab vedotin market report.
• The report also highlights Zilovertamab vedotin‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Zilovertamab vedotin market report also covers the patents information, generic entry and impact on cost cut.
• The Zilovertamab vedotin market report contains current and forecasted Zilovertamab vedotin sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Zilovertamab vedotin market report also features the SWOT analysis with analyst views for Zilovertamab vedotin in potential indications.

Methodology

The Zilovertamab vedotin market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Zilovertamab vedotin Analytical Perspective by DelveInsight

• In-depth Zilovertamab vedotin Market Assessment

This Zilovertamab vedotin sales market forecast report provides a detailed market assessment of Zilovertamab vedotin for potential indication like Diffuse large B cell lymphoma, Bladder cancer, Breast cancer, Chronic lymphocytic leukaemia, Follicular lymphoma, Gastric cancer, Haematological malignancies, Mantle-cell lymphoma, Non-small cell lung cancer, Ovarian cancer, and Pancreatic cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Zilovertamab vedotin sales data uptil 2034.

• Zilovertamab vedotin Clinical Assessment

The Zilovertamab vedotin market report provides the clinical trials information of Zilovertamab vedotin for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Zilovertamab vedotin Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Zilovertamab vedotin Market Potential & Revenue Forecast

• Projected market size for the Zilovertamab vedotin and its key indications
• Estimated Zilovertamab vedotin sales potential (Zilovertamab vedotin peak sales forecasts)
• Zilovertamab vedotin Pricing strategies and reimbursement landscape

Zilovertamab vedotin Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Zilovertamab vedotin Market positioning compared to existing treatments
• Zilovertamab vedotin Strengths & weaknesses relative to competitors

Zilovertamab vedotin Regulatory & Commercial Milestones

• Zilovertamab vedotin Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Zilovertamab vedotin Clinical Differentiation

• Zilovertamab vedotin Efficacy & safety advantages over existing drugs
• Zilovertamab vedotin Unique selling points

Zilovertamab vedotin Market Report Highlights

• In the coming years, the Zilovertamab vedotin market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Zilovertamab vedotin companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Zilovertamab vedotin’s dominance.
• Other emerging products for Diffuse large B cell lymphoma, Bladder cancer, Breast cancer, Chronic lymphocytic leukaemia, Follicular lymphoma, Gastric cancer, Haematological malignancies, Mantle-cell lymphoma, Non-small cell lung cancer, Ovarian cancer, and Pancreatic cancer are expected to give tough market competition to Zilovertamab vedotin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Zilovertamab vedotin in potential indications.
• Analyse Zilovertamab vedotin cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Zilovertamab vedotin sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Zilovertamab vedotin in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Zilovertamab vedotin? How strong is Zilovertamab vedotin’s clinical and commercial performance?
• What is Zilovertamab vedotin’s clinical trial status in each individual indications such as Diffuse large B cell lymphoma, Bladder cancer, Breast cancer, Chronic lymphocytic leukaemia, Follicular lymphoma, Gastric cancer, Haematological malignancies, Mantle-cell lymphoma, Non-small cell lung cancer, Ovarian cancer, and Pancreatic cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Zilovertamab vedotin Manufacturers?
• What are the key designations that have been granted to Zilovertamab vedotin for potential indications? How are they going to impact Zilovertamab vedotin’s penetration in various geographies?
• What is the current and forecasted Zilovertamab vedotin market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Zilovertamab vedotin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Zilovertamab vedotin for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Zilovertamab vedotin? What is the duration of therapy and what are the geographical variations in cost per patient?